Sign in

    Avantika Dhabaria

    registered broker with FINRA (CRD#: 7590781) and is regulated for activities at BofA Securities

    Avantika Dhabaria is an Equity Research Associate at BofA Securities, specializing in life science tools and diagnostics with expertise in covering companies within this sector. She is noted for her analytical abilities in evaluating firms involved in diagnostics and life science technologies, although specific company names and detailed performance metrics such as success rates or ranking on tipster platforms are not publicly documented. Having joined BofA Securities in 2022 following her role as an Equity Research Analyst at Leerink Partners LLC, Dhabaria has built her career on strong educational foundations and research acumen, now based in New York. She is a registered broker with FINRA (CRD#: 7590781) and is regulated for activities at BofA Securities, confirming her professional licensing and regulatory credentials.

    Avantika Dhabaria's questions to Certara (CERT) leadership

    Avantika Dhabaria's questions to Certara (CERT) leadership • Q3 2024

    Question

    Avantika Dhabaria, on for Michael Ryskin, asked about the reallocation of resources to the software business and whether the company is seeing a conversion of services customers into software customers.

    Answer

    Executive John Gallagher highlighted a strong year-to-date software net retention rate of 110%, driven by renewals, expansion, and new logos. He noted a strong correlation between software performance and biosimulation services bookings, which saw strength in Q3 across Tier 1 and Tier 3 customers. This performance, however, was offset by weakness in regulatory services, indicating a synergy between software and biosim services rather than a direct customer conversion.

    Ask Fintool Equity Research AI

    Avantika Dhabaria's questions to Stevanato Group S.p.A. (STVN) leadership

    Avantika Dhabaria's questions to Stevanato Group S.p.A. (STVN) leadership • Q3 2024

    Question

    Avantika Dhabaria of Evercore ISI questioned if the Street's mid-to-high single-digit top-line growth model for 2025 is a reasonable starting point, given current headwinds and the company's long-term targets.

    Answer

    CFO Marco Dal Lago confirmed it is a "reasonable assumption." He noted that while the pace of vial destocking recovery is an uncertainty, the company sees favorable tailwinds in high-performance syringes and other product categories. He also anticipates improvements in the Engineering segment and better financial performance from the new Fishers and Latina plants as they scale.

    Ask Fintool Equity Research AI